Phase II trial of stereotactic radiotherapy for patients with head and neck cancer

Multi-institutional phase II trial of stereotactic radiotherapy for patients with locally advanced head and neck cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1052240008

Enrollment

Registered

2024-04-10

Start date

2024-10-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and neck cancer

Interventions

Stereotactic ablative radiotherapy: 40 Gy in 10 fractions

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with oropharyngeal, hypopharyngeal, laryngeal, oral, maxillary sinus, ethmoid sinus, nasal, or salivary gland cancer 2. Patients not applicable for surgery or radiotherapy for curative intent due to their general condition or social situation 3. Patients previously treated with radiotherapy to the head and neck region

Exclusion criteria

Exclusion criteria: Patients with distant metastasis

Design outcomes

Primary

Measure	Time frame
Time to loco-regional progression	—

Secondary

Measure	Time frame
Response rate, non-hematological acute adverse event rate, late adverse event rate, loco-regional progression-free survival, progression-free survival, overall survival Loco-regional control rate, loco-regional progression-free survival rate, progression-free survival rate, and overall survival rate at 6 months, 1 year, and 2 years Change in QOL score Proportion of patients with out-field local recurrence, proportion of patients with out-field regional lymph node recurrence	—

Measure

Time frame

Response rate, non-hematological acute adverse event rate, late adverse event rate, loco-regional progression-free survival, progression-free survival, overall survival Loco-regional control rate, loco-regional progression-free survival rate, progression-free survival rate, and overall survival rate at 6 months, 1 year, and 2 years Change in QOL score Proportion of patients with out-field local recurrence, proportion of patients with out-field regional lymph node recurrence

—

Contacts

Public ContactShinya Hiraoka

Kyoto University Hospital

shiraok@kuhp.kyoto-u.ac.jp+81-75-751-3762

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026